Share on LinkedInShare on LinkedIn

ARTICLE · 04 MARCH 2020

FULL COURT PRESS: Arthrex Reconsideration Efforts Continue

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

The Federal Circuit continues to be flooded with petitions to revisit its panel decision in Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320, No. 2018-2140 (Fed. Cir. 2019).

United StatesIntellectual Property

The Federal Circuit continues to be flooded with petitions to revisit its panel decision in Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320, No. 2018-2140 (Fed. Cir. 2019). As previously discussed, all three parties in Arthrex filed petitions for en banc rehearing—and those petitions remain pending. Parties in other cases also have asked the full Court to address issues related to Arthrex. See e.g., Bedgear, LLC v. Fredman Bros. Furniture Company, Inc., No. 2018-2082 (petition filed Jan. 8); Customedia Technologies, LLC v. Dish Network Corp., No. 2019-1001 (petition filed Jan. 7); Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals Inc., No. 2019-1368 (petitions filed Dec. 19 & 20); Duke University v. BioMarin Pharmaceutical Inc., No. 2018-1696 (petition filed Dec. 11).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from